Navigation Links
Nephros Announces Rights Offering and Temporary Reduction in Exercise Price for March 2011 Warrants
Date:4/17/2013

RIVER EDGE, N.J., April 17, 2013 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today that it has commenced its previously disclosed rights offering.  On April 17, 2013, the Company will distribute to holders of its common stock and/or warrants one non-transferable subscription right for each share of common stock, and each share of common stock underlying a warrant, held as of April 4, 2013.  The rights offering will expire at 5:00 p.m., Eastern Time, on May 17, 2013, if not extended by the Company in its sole discretion.

On March 4, 2013, the Company filed with the Securities and Exchange Commission (SEC) a registration statement on Form S-1, which was subsequently amended by a registration statement on Form S-1/A filed with the SEC on April 8, 2013.  The registration statement was declared effective by the SEC on April 17, 2013.

Each subscription right will entitle its holder to purchase 0.18776 of a share of common stock of the Company at a subscription price of $0.60 per share.  The Company will not issue fractional shares issuable upon exercise of the subscription rights.  Instead, the Company will round up any such fractional shares to the nearest whole share.

The rights offering includes an over-subscription privilege which permits each rights holder that exercises its rights in full to purchase additional shares of common stock that remain unsubscribed at the expiration of the rights offering.  This over-subscription privilege is subject to the availability and allocation of shares among holders exercising this over-subscription privilege.  Assuming the rights offering is fully subscribed, the Company estimates that it will receive gross proceeds of $3
'/>"/>

SOURCE Nephros, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nephros Reports 2012 Fourth Quarter and Full Year Financial Results
2. Nephros Completes Bridge Financing
3. Nephros and Chem-Aqua Announce Distribution Agreement
4. Nephros Reports Third Quarter 2012 Financial Results
5. Nephros Reports Second Quarter 2012 Financial Results
6. Nephros Reports First Quarter 2012 Financial Results
7. Nephros Receives 510(k) Clearance for Hemodiafiltration System
8. Nephros Appoints John C. Houghton as President and Chief Executive Officer
9. Creekridge Capital Announces Record Volume
10. Veracyte Announces That New Study Suggests The Number Of Patients At Risk For Unnecessary Thyroid Surgery Is Likely On The Rise
11. Rochester Medical Announces Second Quarter 2013 Earnings Conference Call Thursday, April 25, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... AUSTIN, Texas , Sept. 4, 2015  Luminex ... will present at the Morgan Stanley Global Healthcare Conference ... the Grand Hyatt Hotel in New York ... begin at 11:40 a.m. Eastern time on Friday, September ... be accessed at Luminex Corporation,s website at http://www.luminexcorp.com ...
(Date:9/4/2015)... PUNE, India , September 4, 2015 ... "Apheresis Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and ... by Technology and by Product - Global Forecast to ... expected to reach USD 2.5 Billion by 2020, growing ... from 2015 to 2020. Browse 139 ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on ... nervous system (CNS) diseases and trauma, announced today that ... treatment of acute migraine attacks, from the specialist healthcare ... the precise cause of migraines is not fully understood, ...
... Cohera Medical, a rapidly growing medical device company, announced today ... 50 Awards. Cohera Medical was recognized as the 2011 Life ... Executive Officer, Patrick Daly, was named Pittsburgh CEO of the ... by the Pittsburgh Technology Council as a company that is ...
Cached Medicine Technology:Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine 2Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine 3Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards 2Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards 3
(Date:9/4/2015)... ... September 04, 2015 , ... ... is now available at CitiDent. CEREC is a newer method for creating restorations ... time for patients by eliminating the need for multiple appointments, CEREC produces restorations ...
(Date:9/4/2015)... Pittsburgh, PA (PRWEB) , ... September 04, 2015 , ... Many consumers are looking for ... Cups could be their solution. , The patent-pending K Med Cups provide a quick and ... they help to relieve a cold, flu or cough. As a result, they enhance comfort ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... microbiome taking place in Hollywood, Florida October 9-10, 2015 at the Diplomat Resort ... the 2015 symposium are doctors and researchers at the top of their field ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 ... up with victory in the men’s 400 meters final, with an impressive 44.89 seconds ... Championships in San Jose, Costa Rica in August 2015. The 44.64 time is a ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... involving the Pope’s upcoming trip to the United States. , Yisrayl lays out what he ... the Vatican and society is. Yisrayl also provides the meaning of his own name and ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... , ... ... ... ...
... ... ... ... ...
... Cosmetic ... Day , ... 2010 -- Voucher codes website Savoo.co.uk is revealing what mums really want this Mother’s ... are the top three most desired gifts by UK mums., , , , ,Mums work hard ...
... , ... ... ... ...
... ... ... ... ...
... ... , ... (PRWEB) March 4, 2010 -- Champion Nutrition a pioneer in the sports nutrition industry ... years, today announces the signing of World Champion Bantamweight MMA fighter Brian Bowles to ...
Cached Medicine News:Health News:Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line 2Health News:Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line 3Health News:Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line 4Health News:Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line 5Health News:Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line 6Health News:Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line 7Health News:Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line 8Health News:Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line 9Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 2Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 3Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 4Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 5Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 6Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 7Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 8Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 9Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 10Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 11Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 12Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 13Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 14Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 15Health News:Micromet Reports Fourth Quarter and Full Year 2009 Financial Results 16Health News:Voucher Site Savoo.co.uk Reveals What Mum's Really Want This Mother's Day 2Health News:Essilor - 2009 Financial Results 2Health News:Essilor - 2009 Financial Results 3Health News:Essilor - 2009 Financial Results 4Health News:Essilor - 2009 Financial Results 5Health News:Essilor - 2009 Financial Results 6Health News:Essilor - 2009 Financial Results 7Health News:Essilor - 2009 Financial Results 8Health News:Essilor - 2009 Financial Results 9Health News:Essilor - 2009 Financial Results 10Health News:Essilor - 2009 Financial Results 11Health News:Essilor - 2009 Financial Results 12
... The C. Difficile Tox A/B II is a ... difficile toxins A and B in fecal specimens. ... highly sensitive results detecting not only the more ... are toxin A-/B+. It's easy to perform, produces ...
... The TOX A/B QUIK CHEK test is a ... and B in fecal specimens. The test uses ... C. difficile and yields >90% sensitivity and >99% ... detects both toxin A and toxin B, the ...
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
Medicine Products: